Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-09-27 Report Publication Anno…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2024
Report Publication Announcement Classification · 95% confidence The document is a notification letter addressed to non-registered shareholders about the publication of the company's 2024 Interim Report. It informs recipients that the interim report is available electronically on the company's and HKEXnews websites and provides instructions on how to request printed copies. The document also explains the company's adoption of electronic dissemination of corporate communications under the Listing Rules. The content is primarily an announcement about the availability and distribution method of the interim report rather than the report itself. The document length is 9584 characters, which is relatively short and consistent with an announcement rather than a full interim report containing financial statements or substantive financial data. Therefore, this document should be classified as a Report Publication Announcement (RPA).
2024-09-27 English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF INTERIM REPORT 2024
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated September 30, 2024, from Simcere Pharmaceutical Group Limited informing shareholders about the publication of the 2024 Interim Report. It explains the electronic dissemination of corporate communications pursuant to Hong Kong Stock Exchange Listing Rules and solicits shareholders' consent or preferences for receiving future corporate communications electronically or in printed form. The document does not contain the interim report itself or substantive financial data but rather serves as a notice about the availability of the interim report and instructions on how shareholders can access it. The document length is about 12,105 characters, which is relatively short and consistent with a notification letter rather than a full financial report. Therefore, this document is best classified as a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports.
2024-09-27 English
2024 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT 2024' and contains detailed sections such as Corporate Information, Financial Highlights, Company Overview, Management Discussion and Analysis, Corporate Governance, Independent Auditor’s Review Report, and detailed financial statements including Consolidated Statement of Profit or Loss, Statement of Financial Position, and Notes to the Unaudited Interim Financial Report. The report covers the six months ended June 30, 2024, indicating it is a comprehensive financial report for a period shorter than a full fiscal year. The presence of substantive financial data and analysis confirms it is an interim or quarterly report rather than a brief announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-09-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and contains detailed tables and information about changes in issued shares, treasury shares, and share repurchases by Simcere Pharmaceutical Group Limited. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) related to disclosure of share changes and repurchases. The content includes dates, number of shares repurchased, prices, and confirmations of compliance with listing rules. This is a regulatory disclosure about share repurchase and capital changes, not a financial report, earnings release, or management discussion. It fits the category of a company announcement regarding share buybacks and capital structure changes. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive disclosure of share transactions.
2024-09-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued shares or treasury shares, including share buybacks and repurchases. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) related to disclosure of share repurchases and changes in issued shares. The content includes detailed tables of shares repurchased, prices, dates, and confirmations of compliance with listing rules. There is no indication of financial statements, earnings data, management discussion, or other report types. The document is a regulatory disclosure about share repurchase activity and changes in capital structure. This matches the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length is substantial and contains detailed transactional data, not just an announcement or a brief notice, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is POS with high confidence.
2024-09-25 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued shares or treasury shares, including share buybacks and repurchases. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) related to disclosure of share capital changes. The content includes detailed tables of share repurchases, dates, prices, and confirmations of compliance with listing rules. There is no indication of financial statements, earnings data, management discussion, or other report types. The document is a regulatory disclosure about share capital changes and repurchase activities, fitting the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2024-09-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.